Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in Colombian women with invasive cervical cancer

International Journal of Cancer

Volumn 97, Issue 6, 2002, Pages 796-803

  Combita, Alba Lucia ^a,b   Bravo, Maria Mercedes ^a,b   Touzé, Antoine ^a   Orozco, Oscar ^b   Coursaget, Pierre ^a,c  

^a INSERM   (France)

^b Instituto Nacional de Cancerología   (Colombia)

^c UNIVERSITÉ DE TOURS   (France)

Author keywords

Anti VLP antibodies; Cervical cancer; HPV; Virus like particles

Indexed keywords

ANTIBODY; CROSS REACTING ANTIBODY;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CANCER SURVIVAL; COLOMBIA; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPILLOMA VIRUS; PHYLOGENY; PRIORITY JOURNAL; SEROPREVALENCE; UTERINE CERVIX CANCER; VALIDATION PROCESS; VIRUS PARTICLE;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, VIRAL; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; COLOMBIA; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; SEROEPIDEMIOLOGIC STUDIES; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 0037138443     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10153     Document Type: Article

References (61)

1. Estimates of the worldwide incidence of 25 major cancer in 1990
2. Estimates of the worldwide mortality from 25 cancers in 1990
3. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective
4. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
5. Papillomavirus causing cancer: Evasion from host-cell control in early events in carcinogenesis
6. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection
7. Persistence of type specific human papillomavirus infection among cytologically normal women
8. Transience of cervical HPV infection in sexually active young women with normal cervicovaginal cytology
9. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia
10. Natural history of cervico-vaginal papillomavirus infection in young women
11. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high risk area for cervical cancer
12. Human papillomaviruses and cervical neoplasia: A model for carcinogenesis
13. Human papillomavirus and cancer: The epidemiological evidence
14. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica
15. Human papillomavirus and cervical intraepithelial neoplasia grade III/carcinoma in situ: A case-control study in Spain and Colombia
16. Prevalence of human papillomavirus and chlamydia trachomatis infections in the general population from Colombia
17. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillo-mavirus type-16
18. Detection of antibodies against the Human Papillomavirus (HPV) type 16 virions by ELISA using recombinant HPV 16 L1 capsids produced by recombinant baculovirus
19. Evaluation of sero-reactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia
20. Seropositivities to human papillomaviru type 16, 18 or 33 capsids and to Chlamydia trachomatis are markers of sexual behaviour
21. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women
22. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepitheliel neoplasia
23. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome
24. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16
25. Comparison of human papillomavirus type 16, 18, and 6 capsid antibody responses following incident infection
26. Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix
27. Stability over time of serum antibody levels to human papillomavirus type 16
28. Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer
29. Antibodies against human papillomavirus type 6 capsids are elevated in men with previous condylomas
30. Antibodies to human papillomavirus type 11 virus-like particles in sera of patients with genital warts and in control groups
31. Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts
32. Immunoglobulin A, G. and M responses to L1 and L2 capsids of human papillomavirus types 6, 11, 16, 18, and 33 L1 after newly acquired infection
33. Seroreactivity to human papillomavirus types 16, 18, 31 and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions
34. A Survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children
35. Seroresponses to virus-like particles of human papillomavirus type 16, 18, 31, 33, and 45 in San people of Southern Africa
36. Seroresponses to virus-like particles of human papillomavirus type 16, 18, 31, 33, and 45 virus-like particles in South African women with cervical cancer and cervical intraepithelial neoplasia
37. Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women
38. Group-specific differentiation between high and low human papillomavirus serotypes by general primer-mediated PCR and 2 cocktails of oligonucleotides probes
39. The L1 major capsid protein of Human Papillomavirus type 16 variants affects the yield of virus-like particle produced in an insect cells expression system
40. Gene transfer using human papillomaviruses pseudovirions varies according to virus genotype and requires cell surface heparan sulfate
41. Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain
42. Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma
43. Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and -negative women
44. Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions
45. Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls: A longitudinal cohort study
46. Progression from papilloma to carcinoma is accompanied by changes in antibody response to papillomavirus proteins
47. Sexual behavior and papillomavirus exposure in cervical intraepithelial neoplasia: A population-based case-control study
48. Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids
49. Causes of cervical cancer in the philipines: A case-control study
50. Risk factors for cervical cancer in Thailand: A case-control study
51. Concurrent and sequential acquisition of different genital human papillomavirus types
52. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types
53. Production of recombinant virus-like particles from human papillomavirus type 6 and 11, and study of serological reactivities between HPV 6, 11, 16 and 45 by ELISA: Implications for papillomavirus prevention and detection
54. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition
55. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16
56. Immunological analyses of human papillomavirus capsids
57. Analysis of genomic sequences of 95 papillomavirus types: Uniting typing, phylogeny and taxonomy
58. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection
59. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas
60. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization